Market Mover: Kinnate (KNTE) Up at Midday August 5

Equities Staff  |

Kinnate Biopharma Inc (NASDAQ: KNTE) has gained $2.12 (19.07%) and sits at $13.01, as of 11:42:33 est on August 5.

14,757 shares have exchanged hands.

The Company is up 7.88% over the last 5 days and shares lost 3.00% over the last 30 days.

Kinnate anticipates its next earnings on 2022-08-15.

For technical charts, analysis, and more on Kinnate visit the company profile.

About Kinnate Biopharma Inc

Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors.

To get more information on Kinnate Biopharma Inc and to follow the company's latest updates, you can visit the company's profile page here: Kinnate Biopharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content